Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Exploring Mechanisms of Action of ±3,4-methylenedioxymethamphetamine (MDMA)- Assisted Psychotherapy for Posttraumatic Stress Disorder (PTSD)

NCT02102802 is registered in ClinicalTrials.gov with Resilient Pharmaceuticals as lead sponsor.

NCT NCT02102802
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02102802 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Exploring Mechanisms of Action of ±3,4-methylenedioxymethamphetamine (MDMA)- Assisted Psychotherapy for Posttraumatic Stress Disorder (PTSD)
Lead sponsor
Resilient Pharmaceuticals
Phase
Observational
Overall status
Completed
Start date
January 31, 2014
Completion date
August 3, 2015
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

posttraumatic stress disorder